Staging of gynecologic malignancies

Topics in Magnetic Resonance Imaging

Volumn 12, Issue 2, 2001, Pages 105-129

  Ascher, Susan M ^a   Takahama, Junko ^b   Jha, Reena C ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^b NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Magnetic resonance imaging; Ovarian neoplasms; Uterine neoplasms

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL PROTOCOL; DIAGNOSTIC ACCURACY; ENDOMETRIUM CARCINOMA; FEMALE; GYNECOLOGIC CANCER; HUMAN; HYSTERECTOMY; IMAGE ANALYSIS; LYMPH NODE DISSECTION; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY; UTERINE CERVIX CANCER;

ENDOMETRIAL NEOPLASMS; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASM STAGING; OVARIAN NEOPLASMS; UTERINE CERVICAL NEOPLASMS; UTERINE NEOPLASMS;

EID: 0035086984     PISSN: 08993459     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002142-200104000-00004     Document Type: Article

References (70)

1. Staging laparotomy in early ovarian cancer
2. Mistaging of ovarian cancer
3. Mortality from cancer of the uterus in Canada and relationship to screening of cancer of the cervix
4. A comprehensive program for cervical cancer detection and management
5. Uterine cervix
6. Cancer of the uterine cervix
7. Premalignant and malignant disorders of the uterine cervix
8. Stage IB, IIA and IIB cervix cancer, postsurgical staging and prognosis
9. The staging of cervical cancer: Inevitable discrepancies between clinical staging and pathologic findings
10. Cervical carcinoma: Computed tomography and magnetic resonance imaging for preoperative staging
11. Invasive cervical carcinoma: Comparison of MR imaging and surgical findings
12. Clinical Stage I carcinoma of the cervix: Value of MR imaging in determining degree of invasiveness
13. Invasive cervical carcinoma: Role of MR imaging in pretreatment work-up-cost minimization and diagnostic efficacy analysis
14. The role of magnetic resonance imaging in treatment planning of cervical carcinoma
15. Prostate cancer: Effect of post biopsy hemorrhage on interpretation of MR images
16. Carcinoma of the uterus: Use of gadopentetate dimeglumine in MR imaging
17. Carcinoma of the cervix: Value of plain and gadolinium enhanced MR imaging in assessing degree of invasiveness
18. Carcinoma of the cervix: Dynamic MR imaging
19. Dynamic contrast-enhanced MR imaging of uterine cervical cancer: Pharmacokinetic analysis with histopathologic correlation and its importance in predicting the outcome of radiation therapy
20. Prediction of tumor control in patients with cervical cancer: Analysis of combined volume and dynamic enhancement pattern by MR imaging
21. The role of MR imaging in determining surgical eligibility for pelvic exenteration
22. Uterine cervical carcinoma: Comparison of CT and MR findings
23. Uterine cervical carcinoma: Evaluation of pelvic lymph node metastases with MR imaging
24. Comparison of dynamic helical CT and dynamic MR imaging in the evaluation of pelvic lymph nodes in cervical carcinoma
25. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer
26. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer
27. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky Stage IB cervical carcinoma
28. Stage IIB cervical carcinoma: MR evaluation of effect of intra-arterial chemotherapy
29. Surgical staging in endometrial carcinoma: Clinical-pathologic findings of a prospective study
30. Prognosis in endometrial cancer
31. Retroperitoneal lymph node metastases in Stage I carcinoma of the endometrium: Correlation with risk factors
32. Treatment variables in the management of endometrial cancer
33. Risk factors and recurrent patterns in Stage I endometrial cancer
34. Para aortic lymph node evaluation in Stage I endometrial carcinoma
35. Premalignant and malignant disorders of the uterine corpus
36. Prediction of deep myometrial invasion in patients with endometrial cancer: Clinical utility of contrast-enhanced MR imaging-a meta analysis and bayesian analysis
37. Prognostic significance of gross myometrial invasion with endometrial cancer
38. Preoperative assessment of myometrial invasion of endometrial adenocarcinoma by sonography (US) and magnetic resonance imaging (MRI)
39. Estimating the depth of myometrial involvement by endometrial carcinoma: Efficacy of transvaginal sonography vs MR imaging
40. Assessment of myometrial invasion by endometrial carcinoma: Transvaginal sonography vs contrast-enhanced MR imaging
41. The value of ultrasound in preoperative assessment of the myometrial and cervical invasion in endometrial carcinoma
42. Local staging of endometrial carcinoma. Comparison of transvaginal and intraoperative sonography and gross visual inspection
43. Computed tomography of primary, persistent, and recurrent endometrial malignancy
44. Computed tomography in malignant endometrial neoplasms
45. Preliminary experience with gadolinium-enhanced dynamic MR imaging for uterine neoplasms
46. MR imaging evaluation of endometrial carcinoma: Results of an NCI cooperative study
47. Cancer of the endometrium: Value of MR imaging in determining depth of invasion into the myometrium
48. Value of dynamic MR imaging in assessing endometrial carcinoma involvement of the cervix
49. Radiological staging in patients with endometrial cancer: A meta-analysis
50. Uterine changes following dilation and curettage: MRI findings
51. Preoperative staging of endometrial carcinoma: Diagnostic effect of T2 weighted fast spin echo MR imaging
52. Endometrial carcinoma: Assessment of myometrial invasion with plain and gadolinium-enhanced MR imaging
53. Myometrial invasion of endometrial carcinoma: Assessment with dynamic MR and contrast-enhanced T1-weighted images
54. Clinical stage I endometrial carcinoma: Pitfalls in pre-operative assessment with MR imaging
55. Normal uterus and FIGO Stage I endometrial carcinoma: Dynamic gadolinium-enhanced MR imaging
56. Myometrial invasion by endometrial carcinoma: Assessment with plain and gadolinium-enhanced MR imaging
57. Benign and malignant gynecologic disease: Clinical importance of fluid and peritoneal enhancement in the pelvis at MR imaging
58. Ovarian cancer: Comparison of findings with perfluorocarbon-exchanged MR imaging, In 111-CYT-103 immunoscintigraphy, and CT
59. MR imaging of peritoneal disease: Comparison of contrast-enhanced fast multiplanar spoiled gradient-recalled and spin-echo imaging
60. Epithelial ovarian cancer
61. Ovarian epithelial neoplasms: Radiologic-pathologic correlation
62. Tissue characterization in the female pelvis by means of MR imaging
63. Ovarian lesions: Detection and characterization with gadolinium-enhanced MR imaging at 1.5 T
64. Adnexal masses: Transvaginal US and gadolinium-enhanced MR imaging assessment of intratumoral structure
65. Adnexal masses: Accuracy of characterization with transvaginal US and precontrast and postcontrast MR imaging
66. Diagnosis and staging of ovarian cancer: Comparative values of Doppler and conventional US, CT and MR imaging correlated with surgery and histopathologic analysis - Report of the radiology diagnostic oncology group
67. The role of CT in evaluation of ovarian malignancy
68. CT and MRI of ovarian cancer
69. Ovarian cancer: Staging with CT and MR imaging